Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia

The European Respiratory Journal
Stefano AlibertiJulio A Ramirez

Abstract

Recent guidelines suggest that duration of antibiotic therapy for hospitalized patients with community-acquired pneumonia (CAP) can be reduced by individualising treatment based on patient's clinical response. However, the degree of application of this principle in clinical practice is unknown. Duration of therapy was analysed in patients identified from the Community-Acquired Pneumonia Organization database and evaluated with respect to severity of the disease on admission and time to clinical stability (TCS). Among the 2,003 patients enrolled, mean duration of total antibiotic therapy was 11 days. Neither the pneumonia severity index (r(2) = 0.005) nor the CRB-65 (r(2) = 0.004) scores were related to total duration of therapy. Duration of intravenous antibiotic therapy was related to TCS (r(2) = 0.198). Conversely, TCS was not related to duration of either oral (r(2) = 0.014) or total (r(2) = 0.02) antibiotic therapy. Neither TCS nor other characteristics were found to be significantly associated with duration of total therapy by logistic regression analysis (r(2)<0.09). The individualised approach suggested by recent guidelines has not been adopted in current clinical practice. Duration of therapy is not influenced by either...Continue Reading

Citations

Aug 10, 2010·American Journal of Respiratory and Critical Care Medicine·Grant W WatererRichard G Wunderink
Sep 12, 2013·The Journal of Antimicrobial Chemotherapy·Colin MurrayJames D Chalmers
Feb 28, 2013·Current Infectious Disease Reports·Nikole M Scalera, Thomas M File
Jun 26, 2012·European Journal of Internal Medicine·Stefano Aliberti, Francesco Blasi
Aug 27, 2011·Clinics in Chest Medicine·Timothy WiemkenJulio Ramirez
Jan 28, 2014·The Lancet. Respiratory Medicine·Aran Singanayagam, James D Chalmers
May 4, 2010·Pulmonary Pharmacology & Therapeutics·Francesco BlasiFederico Piffer
May 10, 2017·Expert Opinion on Pharmacotherapy·Mario CazzolaMaria Gabriella Matera
Mar 2, 2016·International Journal of Molecular Sciences·Marta Di PasqualeFrancesco Blasi
Nov 11, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sarah H YiJohn A Jernigan
Sep 7, 2018·The Cochrane Database of Systematic Reviews·Jesús López-AlcaldeManuel Gómez-García
Nov 5, 2019·BMJ Open Respiratory Research·Marie StolbrinkJohn D Blakey
Feb 19, 2015·Current Opinion in Infectious Diseases·Stefano AlibertiUNKNOWN DURATION Study Group
Jul 22, 2020·The Journal of Infectious Diseases·Lindsay M Busch, Sameer S Kadri
May 26, 2017·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Abdalsamih M TaebPaul E Marik
Dec 23, 2015·The Australian Journal of Rural Health·Mohamad-Ali Trad, Andreas Baisch
Nov 2, 2019·Lung India : Official Organ of Indian Chest Society·Sandeep NayarRishi Jain
Jan 7, 2015·Hospital Practice·Paul E Marik
Apr 14, 2017·The Medical Journal of Australia·Sarah Sparham, Patrick Gp Charles
Sep 13, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Valerie M VaughnScott A Flanders
Feb 9, 2011·Archivos de bronconeumología·M Luiza de Souza-GalvaoJosé Blanquer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.